Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Staar Surgical ( (STAA) ) just unveiled an update.
On February 1, 2026, STAAR Surgical’s board appointed President and Chief Operating Officer Warren Foust and Chief Financial Officer Deborah Andrews as interim co-chief executive officers, following the previously announced resignation of CEO Stephen C. Farrell effective January 31, 2026. The board has formed a search committee that has already launched a global process to identify a permanent chief executive, considering both internal and external candidates, while Foust and Andrews continue in their existing roles and assume shared responsibility for leading day-to-day operations. As part of the transition, the board approved restricted stock unit awards valued at $375,000 each for Foust and Andrews, with additional protections and potential accelerated vesting for Foust under a new letter agreement if he is not ultimately selected as CEO or is terminated under specified conditions, underscoring the company’s effort to maintain leadership stability and retain key executives during a period of governance change prompted by its recent cooperation agreement with Broadwood Partners.
The most recent analyst rating on (STAA) stock is a Sell with a $20.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
Spark’s Take on STAA Stock
According to Spark, TipRanks’ AI Analyst, STAA is a Neutral.
The score is primarily held down by poor financial performance (large losses and negative operating cash flow) and a bearish technical setup (below key moving averages with negative MACD). Valuation provides limited support given the negative P/E and no dividend, while corporate events are mixed with improved governance but heightened strategic uncertainty after the terminated merger.
To see Spark’s full report on STAA stock, click here.
More about Staar Surgical
STAAR Surgical (NASDAQ: STAA) is a global leader in implantable phakic intraocular lenses for vision correction, dedicated solely to ophthalmic surgery since 1982. The company designs, develops, manufactures and markets its EVO family of Implantable Collamer Lenses, a proprietary, biocompatible lens technology that offers minimally invasive, long-term vision correction as an alternative to glasses or contact lenses, with more than 3 million lenses sold in over 75 countries from its headquarters and facilities in California and Switzerland.
Average Trading Volume: 1,342,168
Technical Sentiment Signal: Strong Sell
Current Market Cap: $942.6M
Learn more about STAA stock on TipRanks’ Stock Analysis page.